Endo International plc (NASDAQ:ENDP) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Endo International plc (NASDAQ:ENDP) gained 4.47 Percent and closed its previous trading session at $8.88. The stock traded with the average Volume of 5.35 Million at the end of last session.
The company reported its last earnings Actual EPS of $0.67/share. While, the analyst predicted that the company could provide an EPS of $0.55/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.12/share which shows an Earnings Surprise of 21.8 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Endo International plc (NASDAQ:ENDP) as Buy, 0 analysts given Outperform signal, 6 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 32.86% where SMA50 and SMA200 are 45.94% and 24.6% respectively.
The company shows its Return on Assets (ROA) value of -20.3%. The Return on Equity (ROE) value stands at -461.4%. While it’s Return on Investment (ROI) value is -9.1%.
Endo International plc (NASDAQ:ENDP) currently has a Weekly Volatility of 7.94% percent while its Monthly Volatility is at 5.67% percent. While talking about Performance of the Stock, Endo International plc currently has a Weekly performance of 14.58%, monthly performance percentage is 42.77 percent, Quarterly performance is 25.96 percent, 6 months performance shows a percent value of 15.03% and Yearly Performance is -20.14 percent.
Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.